BioNTech Investor Day Presentation Deck

Advancing toward our long-term vision 1 marketed vaccine Market leader in COVID-19 vaccines 16 programs in 21 clinical trials 5 randomized Phase 2 trials Oncology 1 Phase 1 program 10+ preclinical programs Infectious diseases Next-gen or variant adapted COVID-19 vaccines Multiple product launches in next 3-5 years 5-10 IND submissions per year Maintain and deepen COVID-19 vaccine leadership Approved products across various disease areas Driving transformation today Mid-term goals Long-term vision By 2030, we aim to be a multi-product global biotechnology leader, aspiring to address the world's most pressing health challenges with pioneering, disruptive technologies delivered at scale BIONTECH 153

View entire presentation